Clinical Trial Update: Capecitabine (Xeloda) and Lapatinib (Tykerb) as First-line Therapy in HER2/Neu-positive Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluated first-line capecitabine (Xeloda) with lapatinib (Tykerb) for HER2-positive breast cancer; the study was terminated and results were post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Capecitabine (capecitabine)
• Lapatinib (Lapatinib)

Snippet

Sponsor: Rutgers, The State University of New Jersey | Conditions: Breast Cancer, Metastatic Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-03-21